Sangamo’s ST-920 demonstrates evidence of clinical benefit
Phase 1/2 research shows that treatment could be very effective against Fabry disease
Read More
Tag: ST-920
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
